Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Long-Term Investments (2022 - 2023)

Gain Therapeutics (GANX) has 2 years of Long-Term Investments data on record, last reported at $988388.0 in Q1 2023.

  • For Q1 2023, Long-Term Investments changed N/A year-over-year to $988388.0; the TTM value through Mar 2023 reached $988388.0, changed N/A, while the annual FY2022 figure was $1.9 million, N/A changed from the prior year.
  • Long-Term Investments reached $988388.0 in Q1 2023 per GANX's latest filing, down from $1.9 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $4.9 million in Q2 2022 and bottomed at $988388.0 in Q1 2023.